Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac CARE Trial
ISRCTN24439460Phase 2Completed
- Sponsor
- ACCORD - University of Edinburgh & NHS Lothian co-sponsors
- Start
- Sep 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of candesartan and carvedilol in Cardiac damage and chemotherapy-induced cardiotoxicity (CIC) (2 arms), sponsored by ACCORD - University of Edinburgh & NHS Lothian co-sponsors. Primary endpoint: Left ventricular ejection fraction. Started Sep 2017; status: completed.
02
Drugs
candesartancarvedilol
03
Conditions
Cardiac damagechemotherapy-induced cardiotoxicity (CIC)
Beyond the preview
Go deeper on ISRCTN24439460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24439460.